
    
      OBJECTIVES: I. Evaluate the response rate and toxic effects of paclitaxel by 96 hour
      continuous infusion in chemotherapy naive and chemotherapy exposed patients with recurrent or
      metastatic squamous cell carcinoma of the head and neck.

      OUTLINE: Patients receive paclitaxel as a 96 hour continuous IV infusion. Courses repeat
      every 3 weeks for a maximum of 12 courses. Patients with disease progression after 2 courses
      or with unacceptable toxicity at any time are removed from study.

      PROJECTED ACCRUAL: Approximately 109 patients will be accrued for this study over 4 years.
    
  